## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

213330Orig1s000

## **OFFICER/EMPLOYEE LIST**

MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE

FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** October 11, 2020

**TO:** Administrative file for NDA 213330

**FROM:** Maryam Changi, Regulatory Health Project Manager

Division of Division of Regulatory Operations for Cardiology, Hematology,

Endocrinology, & Nephrology, Office of Regulatory Operations

**SUBJECT:** Officer/Employee List for NDA 213330

**APPLICATION/DRUG:** NDA 213330,

• Labetalol Hydrochloride in Dextrose Injection (preservative free) 200 mg/200 mL (1 mg/mL)

Labetalol Hydrochloride in Sodium Chloride Injection (preservative free) 100 mg/100 mL, 200 mg/200 mL, 300 mg/300 mL

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Last name, First name (alphabetize by last name)

Adams, Grafton

Aidoo, Mariette

Aldridge, Allison

Best, Jeanine A

Bradley, Marie

Buck, Heather

Changi, Maryam

Cao, Christian

Claffey, David

Fromm, Edward J

Kambhampati, Rao V

Mehta, Hina

Monteleone, Michael V.

Pan, Xiaolei

Patel, Zarna

Sapru, Mohan

Stockbridge, Norman

Woronow, Daniel

-----

This is a representation of an electronic record that was signed
electronically. Following this are manifestations of any and all
electronic signatures for this electronic record.

/s/

MARYAM K CHANGI

11/09/2020 12:45:33 PM